Christopher Yusuf Akhunbay-Fudge

39 posts

Christopher Yusuf Akhunbay-Fudge banner
Christopher Yusuf Akhunbay-Fudge

Christopher Yusuf Akhunbay-Fudge

@CA_Fudge

Neurosurgery Registrar and PhD researcher investigating #Glioblastoma biology. Scuba diver, Mushroom forager, Bonsai enthusiast. Views are my own.

Katılım Mart 2020
531 Takip Edilen204 Takipçiler
Christopher Yusuf Akhunbay-Fudge
With it being hashtag #Brain #Tumour Awareness month this is a timely addition to the literature. Key findings are a cell-intrinsic invasion signature and the unexpected migratory potential of #cancer cells detected by a novel algorithm (DyPheT)
English
0
0
0
25
Christopher Yusuf Akhunbay-Fudge
Fantastic exhibition showcasing the great work supported by @LDShospcharity. It has been a true honour and privilege to be a recipient of their generous funding. They make a real difference to patients.
Leeds Hospitals Charity@LDShospcharity

We are so excited to launch ‘Our Research Story’ exhibition showcasing the people behind life-changing research taking place right here in Leeds!💜 More info: leedshospitalscharity.org.uk/News/ecr @LeedsHospitals @UniversityLeeds @LeedsArtUni

Leeds, England 🇬🇧 English
0
0
4
211
Christopher Yusuf Akhunbay-Fudge retweetledi
Sky News
Sky News@SkyNews·
'We hope this inspires surgeons worldwide to keep pushing the surgical envelope.' Drs. James Robin and Jiten Parmar hail their "pioneering surgery" after removing a tumor through a woman's eye socket. trib.al/qeQpuBB 📺 Sky 501, Freeview and YouTube
English
9
18
53
33.9K
Christopher Yusuf Akhunbay-Fudge retweetledi
Leeds Teaching Hospitals
Leeds Teaching Hospitals@LeedsHospitals·
🚨 Groundbreaking in Leeds! Surgeons at Leeds Teaching Hospitals made history, removing a skull base tumour through the eye socket using a minimally invasive technique. Ruvimbo Kaviya, 40, is the UK’s first patient to benefit from this innovative surgery by Mr. Asim Sheikh & Mr. Jiten Parmar. Full story👉 shorturl.at/1G7m4 #MedicalInnovation #LeedsTeachingHospitals #HealthcareAdvancements
English
4
24
162
15K
Christopher Yusuf Akhunbay-Fudge retweetledi
Asim Sheikh
Asim Sheikh@ASheikhNeuro·
New approaches and technologies are only good if they benefit patients. Endoscopic Transorbital excision of cavernous sinus meningioma. Quick recovery, excellent access to tumour, complete excision with good operative views. Normal vision and eye movements post op. Images shared with permission and consent from patient. @SkullBaseLeeds @LTHTNEURO @AlbertoEqDS
Asim Sheikh tweet mediaAsim Sheikh tweet mediaAsim Sheikh tweet mediaAsim Sheikh tweet media
English
34
6
38
3.2K
Christopher Yusuf Akhunbay-Fudge retweetledi
Dr. Renee Read
Dr. Renee Read@RRead_Lab·
If you're interested in exploring postdoctoral opportunities in @NeuroOnc, you're invited to apply to a special postdoctoral recruiting event at Winship Cancer Institute of Emory University this March. Join our wonderful brian tumor research community! 🤩 winshipcancer.emory.edu/education/post…
English
2
10
28
2.7K
Christopher Yusuf Akhunbay-Fudge retweetledi
Dr Vassili Crispi 🇮🇹🏳️‍🌈
Honoured to present at #SNO2023 one of the projects from my neurosurgical academic foundation programme on the @LeedsHospitals 10-year experience of Gamma Knife for patients with cerebral metastases. An exciting programme and beautiful location by @NeuroOnc @LeedsNeuro
Dr Vassili Crispi 🇮🇹🏳️‍🌈 tweet mediaDr Vassili Crispi 🇮🇹🏳️‍🌈 tweet mediaDr Vassili Crispi 🇮🇹🏳️‍🌈 tweet media
Vancouver, British Columbia 🇨🇦 English
1
7
24
2.7K
Leeds Hospitals Charity
Leeds Hospitals Charity@LDShospcharity·
During Brain Tumour Awareness Week, we want to acknowledge your donations that helped fund brain cancer research at Leeds Teaching Hospitals NHS Trust. In 2021, we granted £200,000 to Christopher Fudge's research on glioma cells and tumour recurrence after surgery.
Leeds Hospitals Charity tweet mediaLeeds Hospitals Charity tweet mediaLeeds Hospitals Charity tweet media
English
1
5
17
3.6K
Christopher Yusuf Akhunbay-Fudge retweetledi
Stephen Price💙
Stephen Price💙@Sjp58Price·
Such an important study. Congratulations to all the authors for this practice changing study.
NEJM@NEJM

Late breaking at #ASCO23: Mutations in isocitrate dehydrogenase 1 or 2 are common in low-grade glioma. The IDH inhibitor vorasidenib improved progression-free survival as compared with placebo. Full results of the INDIGO trial: nej.md/3N8N5dU

English
0
3
7
2K